Spinraza RESPOND Trial Enrolling Children Not Helped by Zolgensma

Spinraza RESPOND Trial Enrolling Children Not Helped by Zolgensma

307168

Spinraza RESPOND Trial Enrolling Children Not Helped by Zolgensma

Biogen is continuing to actively recruit patients for its Phase 4 RESPOND trial, which is evaluating the benefits of Spinraza (nusinersen) in infants and children with spinal muscular atrophy (SMA) who responded poorly to the gene therapy Zolgensma. Participants are now being enrolled at 10 sites in the U.S. and one in Italy, with more sites expected to open; further information on contacts and locations can be found here. As of July 31, nine patients had been enrolled in RESPOND…

You must be logged in to read/download the full post.